January 30, 2018 / 1:16 PM / 6 months ago

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

Jan 30 (Reuters) - Fibrocell Science Inc:

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

* FIBROCELL SCIENCE INC - FCX-007, CO’S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below